In This Article:
-
Net Loss (Q3 2024): $10.1 million or $1.70 per share.
-
Net Loss (Q3 2023): $12.2 million or $2.13 per share.
-
Net Loss (9 months ended September 30, 2024): $33.8 million or $5.77 per share.
-
Net Loss (9 months ended September 30, 2023): $35.7 million or $6.96 per share.
-
Research and Development Expenses (Q3 2024): $9.7 million.
-
Research and Development Expenses (Q3 2023): $10.4 million.
-
Research and Development Expenses (9 months ended September 30, 2024): $29.6 million.
-
Research and Development Expenses (9 months ended September 30, 2023): $29.5 million.
-
General and Administrative Expenses (Q3 2024): $3.8 million.
-
General and Administrative Expenses (Q3 2023): $4.8 million.
-
General and Administrative Expenses (9 months ended September 30, 2024): $13.4 million.
-
General and Administrative Expenses (9 months ended September 30, 2023): $13.8 million.
-
Cash and Cash Equivalents (October 2024): $31.6 million.
-
Shares of Common Stock Outstanding: Approximately 8.5 million.
-
Net Proceeds from October 2024 Offerings: Approximately $10.8 million.
Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Curis Inc (NASDAQ:CRIS) reported encouraging early data from their PCNSL study, showing three complete responses and two partial responses among 10 evaluable patients.
-
The company is actively engaging with regulatory authorities to define the registrational path for Emavusertib, indicating progress towards potential approval.
-
Curis Inc (NASDAQ:CRIS) has shown promising results in their leukemia study, with six of 11 evaluable patients achieving an objective response.
-
The company completed a registered direct offering and concurrent private placement, raising approximately $10.8 million, strengthening their financial position.
-
Curis Inc (NASDAQ:CRIS) expects its existing cash and cash equivalents to support planned operations into mid-2025, providing a stable financial outlook.
Negative Points
-
Curis Inc (NASDAQ:CRIS) reported a net loss of $10.1 million for the third quarter of 2024, indicating ongoing financial challenges.
-
Research and development expenses remain high, with $9.7 million spent in the third quarter of 2024, reflecting significant ongoing investment needs.
-
The company faces challenges in patient enrollment for their triplet study, impacting the progress of clinical trials.
-
There is uncertainty regarding the FDA's approval path for Emavusertib, which could affect the timeline for bringing the drug to market.
-
Curis Inc (NASDAQ:CRIS) must prioritize between multiple promising programs, which could lead to resource allocation challenges.